Jinan Zhuocheng Bio-Tech Co., Ltd.

A clear trend is emerging in China’s veterinary API industry: leading manufacturers are increasingly evolving from conventional API producers into integrated chemical and pharmaceutical manufacturing platforms with capabilities covering key raw materials, intermediates, APIs, and, in some cases, finished formulations.

At the center of this transition are pharmaceutical intermediates.

For many veterinary APIs, key intermediates account for a significant share of total manufacturing costs. Florfenicol provides a representative example. Its key chiral intermediate, D-ethyl ester, has historically represented a substantial portion of the overall production cost. The development of biocatalytic and other advanced synthesis technologies has significantly reduced intermediate production costs, subsequently changing the cost structure and competitive dynamics of the API market.

Intermediate Self-Supply Is Becoming an Important Cost-Control Strategy

Over the past several years, prices for some veterinary API intermediates have remained relatively low. In August 2026, Zhejiang Medicine-related pharmaceutical company reports indicated that veterinary API intermediate prices had remained at low levels for an extended period, with future market developments expected to depend largely on supply-side adjustments and the pace of recovery in downstream livestock demand.

For API manufacturers, this means that cost competitiveness is increasingly determined not only by purchasing prices, but also by the ability to control upstream production and manufacturing processes.

Florfenicol is a representative example.

Historically, the production of D-ethyl ester involved relatively complex processes and lower yields. With the introduction of biocatalytic and other improved synthesis technologies, production costs have been significantly reduced, while raw-material consumption and energy requirements have also been improved.

The impact of these technological improvements extends beyond the intermediate itself. Lower intermediate costs can directly affect the manufacturing economics of the downstream API.

As a result, for key intermediates with high consumption volumes, the ability to manufacture them internally is becoming an increasingly important factor in both cost control and supply stability.

Two Supply Chain Models Are Emerging

The current veterinary API intermediate sector is developing along two major paths.

The first is full supply chain integration.

Some manufacturers are extending their production capabilities upstream, starting from basic chemical raw materials and developing technologies covering multiple stages of the manufacturing process. By integrating intermediates and APIs, these companies can reduce dependence on external suppliers while improving production planning, quality control, and supply stability.

The second model is key-intermediate self-production combined with external supply.

Rather than integrating every production stage, some companies focus on intermediates where they have technological, cost, or scale advantages. These intermediates are used internally for API manufacturing while also being supplied to customers in pharmaceutical, animal health, agricultural chemical, and related industries.

This model can create additional economies of scale. Internal consumption provides a stable base of demand, while external sales improve capacity utilization and provide manufacturers with direct market information and customer relationships.

The two models are not necessarily substitutes. Instead, they reflect different product portfolios, technological capabilities, and business strategies.

Intermediate Manufacturing Requires Significant Technical and Compliance Capabilities

Pharmaceutical intermediates are not simply upstream commodities.

Some key intermediates involve high-temperature or high-pressure reactions, anhydrous or oxygen-free environments, specialized solvent systems, and complex crystallization and separation processes. These operations require strong capabilities in process control, equipment safety, purification, quality management, and environmental protection.

For example, the production of certain borohydride-based intermediates requires strict control of reaction conditions, together with appropriate explosion-proof and corrosion-resistant equipment and precise temperature management. High-purity intermediates may also require sophisticated crystallization, separation, and impurity-control technologies.

As a result, competition in the intermediate sector involves more than production capacity. It also depends on process technology, manufacturing scale, equipment capabilities, safety management, and environmental compliance.

This helps explain why smaller manufacturers with limited technological and operational capabilities may face greater pressure when the market enters a prolonged period of price competition.

Supply-Side Restructuring Is Raising the Industry Entry Threshold

The prolonged period of relatively low intermediate prices has also accelerated the adjustment of inefficient production capacity.

At the same time, the requirements for new production projects are becoming increasingly comprehensive.

In recent years, new veterinary API expansion projects have placed greater emphasis on GMP compliance, environmental protection, production safety, automation, and quality management. New capacity is no longer simply about adding production lines; manufacturers are increasingly focusing on production efficiency and overall compliance capabilities.

Environmental regulation is another important factor affecting the supply structure.

For intermediates that fall within the scope of new chemical substance management, manufacturers need to assess, based on the specific substance and applicable regulations, whether environmental registration or other compliance procedures are required.

As regulatory requirements become more comprehensive, new market entrants may face higher compliance investments and longer development timelines.

Consequently, the competitive threshold in the intermediate sector is increasingly determined not only by manufacturing costs, but also by a company's ability to continuously meet requirements related to safety, environmental protection, quality, and regulatory compliance.

Three Key Changes in the Veterinary API Intermediate Market

Several structural changes are becoming increasingly visible in the veterinary API intermediate market.

First, the importance of intermediate self-sufficiency is increasing.

For key intermediates that represent a significant portion of manufacturing costs, internal production can reduce exposure to external price fluctuations and improve supply reliability. Process innovation can also create substantial cost advantages and potentially reshape the competitive position of a specific API.

Second, the external intermediate supply market may become increasingly concentrated among larger manufacturers.

Intermediate production requires continuous investment in equipment, process development, safety systems, environmental protection, and quality management. As regulatory requirements increase, smaller suppliers without sufficient technological or operational resources may face greater pressure.

For larger manufacturers, production scale and vertical integration can help distribute fixed costs and provide a more stable supply platform.

Third, downstream livestock demand remains an important factor in determining market prices.

The current relatively low price levels of some intermediates are closely related to supply-demand conditions. Supply-side capacity adjustments can change the market structure, but a sustained market recovery will also depend on downstream livestock production, veterinary drug demand, and purchasing cycles.

Therefore, future movements in intermediate prices are unlikely to be determined by production costs alone. Instead, they will reflect the combined effects of supply structure, manufacturing costs, and downstream demand.

From API Manufacturing to Supply Chain Capability

The growing focus on key intermediates represents a broader change in the competitive logic of the veterinary API industry.

In the past, manufacturers primarily competed on production availability and capacity. Competition then increasingly shifted toward production costs. Going forward, manufacturers will need to address three fundamental questions:

Is the cost structure competitive?
Is the supply reliable?
Can the manufacturing system consistently meet quality, environmental, safety, and regulatory requirements?

As a result, competitive veterinary API manufacturers may increasingly evolve beyond the traditional role of API producers and develop into integrated manufacturing platforms with capabilities in intermediate synthesis, large-scale production, quality control, supply chain management, and regulatory compliance.

For international veterinary pharmaceutical companies and API buyers, this development also changes how suppliers may be evaluated.

In addition to API quality and price, factors such as the source of key intermediates, supply chain stability, manufacturing technology, production consistency, and long-term compliance capabilities are likely to become increasingly important considerations when selecting and developing strategic suppliers.